Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-negative Breast Cancer × Anthracyclines × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 Leukemia, Myeloid, Acute 7 Triple Negative Breast Neoplasms 3 Leukemia 3 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid 1 HER2-negative Breast Cancer 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡